KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2025)

Adaptive Biotechnologies' Debt to Equity history spans 4 years, with the latest figure at $0.58 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 11.41% year-over-year to $0.58; the TTM value through Dec 2025 reached $0.58, down 11.41%, while the annual FY2025 figure was $0.58, 11.41% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.58 at Adaptive Biotechnologies, down from $0.64 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.74 in Q2 2025 and bottomed at $0.27 in Q4 2022.
  • The 4-year median for Debt to Equity is $0.58 (2025), against an average of $0.55.
  • The largest annual shift saw Debt to Equity surged 65.21% in 2024 before it fell 11.41% in 2025.
  • A 4-year view of Debt to Equity shows it stood at $0.27 in 2022, then soared by 56.91% to $0.42 in 2023, then skyrocketed by 55.3% to $0.66 in 2024, then dropped by 11.41% to $0.58 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Debt to Equity are $0.58 (Q4 2025), $0.64 (Q3 2025), and $0.74 (Q2 2025).